Miami, FL – Teva Pharmaceutical Industries Limited discussed its strategies for growth and innovation during the Goldman Sachs 45th Annual Global Healthcare Conference. The company’s President and CEO, Richard Francis, shared insights on Teva’s Pivot to Growth initiative and how the company is reallocating resources to drive innovation and sustainable growth.

Francis highlighted the importance of innovation as a key driver for the company’s future growth, emphasizing the four pillars of Teva’s growth strategy. He discussed the company’s focus on delivering growth engines, stepping up innovation, creating a sustainable generics powerhouse, and streamlining business operations through effective capital allocation.

The CEO emphasized the significance of making strategic choices in allocating resources and capital to drive performance and achieve long-term goals. He discussed the company’s focus on building capabilities, launching innovative products, and maintaining a strong presence in the generics market.

Francis also addressed the company’s outlook on achieving revenue growth and EBIT margins by 2027, emphasizing the importance of executing on the strategic plan to drive performance and capitalize on growth opportunities. He discussed the company’s approach to investing in new products and prioritizing innovation to drive future success.

The discussion also touched on Teva’s pipeline of innovative products, including TL1A, olanzapine, and ICS/SABA, highlighting the company’s focus on developing high-quality, differentiated therapies to meet patient needs. Francis discussed the potential for these products to drive growth and contribute to the company’s long-term success.

In conclusion, Francis reiterated the company’s commitment to growth, innovation, and driving performance across its portfolio. He emphasized the importance of strategic planning, effective resource allocation, and a performance-based culture to achieve Teva’s long-term goals and deliver value to patients and shareholders.